768 reports of this reaction
3.3% of all BASILIXIMAB reports
#5 most reported adverse reaction
KIDNEY TRANSPLANT REJECTION is the #5 most commonly reported adverse reaction for BASILIXIMAB, manufactured by Novartis Pharmaceuticals Corporation. There are 768 FDA adverse event reports linking BASILIXIMAB to KIDNEY TRANSPLANT REJECTION. This represents approximately 3.3% of all 23,408 adverse event reports for this drug.
Patients taking BASILIXIMAB who experience kidney transplant rejection should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
KIDNEY TRANSPLANT REJECTION is moderately reported among BASILIXIMAB users, representing a notable but not dominant share of adverse events.
In addition to kidney transplant rejection, the following adverse reactions have been reported for BASILIXIMAB:
The following drugs have also been linked to kidney transplant rejection in FDA adverse event reports:
KIDNEY TRANSPLANT REJECTION has been reported as an adverse event in 768 FDA reports for BASILIXIMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
KIDNEY TRANSPLANT REJECTION accounts for approximately 3.3% of all adverse event reports for BASILIXIMAB, making it a notable side effect.
If you experience kidney transplant rejection while taking BASILIXIMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.